Novo Nordisk, Jiangsu Hengrui sign up to $2.6B licensing deal for oral obesity and diabetes candidate
Novo Nordisk, Jiangsu Hengrui sign up to $2.6B licensing deal for oral obesity and diabetes candidate HRS-1596
- Agreement grants Novo Nordisk global rights to HRS-1596 outside Greater China from Jiangsu Hengrui Pharmaceuticals.
- HRS-1596 is a phase 1-ready oral GLP-1/GIP candidate targeted for obesity and diabetes treatment.
- Deal expands Novo Nordisk's pipeline of oral peptide therapies for metabolic diseases.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.